Biokine Therapeutics

Company Overview

Snapshot

Founded in July 2000 by Prof. Amnon Peled, Biokine Therapeutics operates with 1–10 employees. The company has secured funding across two rounds from Clal Biotechnology Industries (CBI) and Amnon Peled, with its lead drug candidate, BKT140/BL8040, currently undergoing Phase 2a clinical trials for acute myeloid leukemia.

Business overview

Biokine Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel drugs for cancer treatment. The company's core technology involves identifying molecular and cellular mechanisms that regulate tumor development and metastasis, leading to a suite of unique approaches to target cancer. Its lead drug candidate, BKT140/BL8040, is a high-affinity CXCR4 antagonist being investigated for refractory and relapsed acute myeloid leukemia and stem cell mobilization. Biokine Therapeutics operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, serving markets such as the United States.

Strategic signal

In October 2018, BioLineRx increased its stake in BL-8040, Biokine Therapeutics' lead oncology platform. This move signals strong confidence in the drug's potential and its advanced stage of development for multiple oncology indications, suggesting a positive outlook for future clinical and commercial milestones.

Company Intelligence Q&A

What is Biokine Therapeutics' primary focus?

Biokine Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel drugs for cancer treatment and stem cell mobilization.

Who founded Biokine Therapeutics and when?

Biokine Therapeutics was founded in July 2000 by Prof. Amnon Peled, a leading cancer and stem cell biologist.

What is the status of Biokine Therapeutics' lead drug candidate, BKT140/BL8040?

The lead drug candidate, BKT140/BL8040, is currently in Phase 2a clinical trials for the treatment of refractory and relapsed acute myeloid leukemia, and also in a Phase 1 clinical trial for stem cell mobilization.

What was a significant development regarding BL-8040 in October 2018?

In October 2018, BioLineRx increased its stake in BL-8040, Biokine Therapeutics' lead oncology platform, highlighting its advanced development for multiple oncology indications.

Did Biokine Therapeutics receive any grants?

In March 2009, Biokine Therapeutics received a grant from the Office of the Chief Scientist.